Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Renaparin-Treated Kidneys for Transplantation
NCT03773211Phase 1Completed
- Sponsor
- Corline Biomedical
- Start
- Feb 2019
- Primary completion
- Apr 2020
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in delayed graft function (DGF) and ischemia-reperfusion injury (IRI) comparing Renaparin Arm with Placebo Arm (2 arms). Primary endpoint: Adverse Events at 30 days. Started Feb 2019; status: completed.
02
Drugs
Renaparin
03
Conditions
delayed graft function (DGF)ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT03773211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773211.